Molecular Pharmacology (USA) Company Description
Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States.
The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain.
Its products are available in various dosage forms, formulations, line extensions, and package configurations.
The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe.
It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient.
The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.
| Country | United States |
| Industry | Shell Companies |
| Sector | Financials |
| Employees | 1 |
| CEO | Jeffrey Edwards |
Contact Details
Address: Drug Discovery Centre Perth, Washington 6007 Australia | |
| Phone | 61 8 9443 3011 |
Stock Details
| Ticker Symbol | MLPH |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| ISIN Number | US60852T1097 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey David Edwards | Chief Executive Officer, President, Chief Financial Officer and Director |